View all dosages and compare prices:
Buy Retatrutide — all dosages →
Retatrutide 12 mg
PEN PEPTIDE · Triple agonist
Next-generation triple agonist · 12 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE
12 mgShips today · before 19:00
Delivery Sat, Jun 27 · Nova Poshta
Retatrutide 12 mg from PEN PEPTIDE — stabilized pen with triple GLP-1/GIP/glucagon agonist. 120 units of 100 mcg each. Optimal for dose escalation phase. MSSPT technology.
Specialist support included in the price
A personal DOZA specialist guides you throughout the entire course — from first consultation to results.
Triple agonist — next generation
Retatrutide — a triple GLP-1/GIP/glucagon agonist. Investigational Phase 3 molecule by Eli Lilly. Not approved by FDA/EMA.
Manufacturer: PEN PEPTIDE
PEN PEPTIDE — a brand of peptide products.
Free consultation
Benefits
- ✓Triple mechanism of action — only GLP-1 + GIP + glucagon agonist
- ✓12 mg — optimal pen for escalation phase (2–6 mg/week)
- ✓Pre-Mixed stabilized pen — ready solution, no reconstitution needed
- ✓MSSPT technology — tolerant to short-term temperature fluctuations
- ✓Purity ≥98% — GMP-certified manufacturing in Europe
- ✓Up to 24% weight loss over 48 weeks (Phase 2 study, NEJM 2023)
- ✓Cold chain delivery in thermoboxes with cooling elements (2–8°C) across Ukraine
- ✓Free 24/7 DOZA specialist support throughout the entire course
Retatrutide 12 mg (PEN PEPTIDE) — detailed description
Retatrutide 12 mg from PEN PEPTIDE — triple agonist of GLP-1, GIP and glucagon receptors in a stabilized pen.
The 12 mg pen contains 120 units of 100 mcg each. Dosing table:
• 1 unit = 100 mcg
• 10 units = 1 mg
• 20 units = 2 mg
• 40 units = 4 mg
• 60 units = 6 mg
Optimal for escalation phase — from 2 mg to 6 mg per week. Lasts 3–6 weeks depending on current dose.
Formula stabilized using MSSPT (Molecular Structure Stabilization Process Technology) — maintains structural integrity and bioactivity even during temporary temperature deviations above 8°C during transportation.
Purity ≥98%. Manufactured in certified GMP laboratories in Europe.
How it works — mechanism of action
Retatrutide is the only triple agonist of GLP-1 + GIP + glucagon. Acts on three receptors simultaneously:
1. GLP-1 — reduces appetite, slows gastric emptying, regulates glucose levels.
2. GIP — enhances GLP-1 effects and improves fat tissue metabolism.
3. Glucagon — activates lipolysis (fat breakdown) and thermogenesis (calorie burning).
In the Phase 2 clinical trial (NEJM, 2023), participants on 12 mg dose lost up to 24% body weight over 48 weeks — the best result among all weight loss drugs.
Dosage
Standard starting dose: 2 mg once weekly subcutaneously.
Gradual escalation: 2 mg → 4 mg → 6 mg → 8 mg depending on tolerability and results.
Subcutaneous injection in abdomen, thigh, or upper arm. Same day of the week.
Do not increase dose until hunger returns. Maintain balanced nutrition.
What's in the kit
Стабілізована шприц-ручка PEN PEPTIDE Retatrutide 12 мг.
• 1 ручка = 12 мг ретатрутиду (120 юнітів × 100 мкг)
• 1 юніт = 100 мкг, 10 юнітів = 1 мг, 20 юнітів = 2 мг, 40 юнітів = 4 мг, 60 юнітів = 6 мг
• Pre-Mixed — готовий розчин, не потребує розведення
• Технологія MSSPT — стабілізована формула
• Чистота ≥98%
Composition
Діюча речовина: ретатрутид (retatrutide) 12 мг загалом у ручці (120 юнітів × 100 мкг).
Стабілізована формула (MSSPT — Molecular Structure Stabilization Process Technology):
• Оптимізовані буферні компоненти для підтримки стабільного pH
• Антиоксиданти для запобігання окислювальній деградації
• Стабілізуючі агенти для запобігання агрегації
Чистота ≥98%. Вироблено на GMP-сертифікованих лабораторіях.
Storage
Зберігати в холодильнику при температурі 2–8°C. Не заморожувати.
Стабілізована формула (MSSPT) — толерантна до короткочасних відхилень температури вище 8°C під час транспортування.
Зберігати ручку в оригінальній упаковці для захисту від світла.
Після першого використання — зберігати при 2–8°C, використати протягом терміну придатності.
Не зберігати з приєднаною голкою.
Тільки для підшкірного введення.
Клінічні дослідження
Retatrutide (LY3437943 12 mg) — потрійний агоніст GLP-1 + GIP + глюкагон Eli Lilly. Phase 3 (TRIUMPH-1, TRIUMPH-2). Очікуване схвалення FDA — 2026–2027. На /research зібрана уся доказова база Phase 2 та статус trials.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial (NEJM 2023)PubMed · 2023
- TRIUMPH-1: Phase 3 study of LY3437943 in adults with obesityClinicalTrials.gov · 2024
Retatrutide is an investigational drug currently in Phase 3 clinical trials. Not approved by FDA, EMA or МОЗ України as of 2026.
View full клінічні дослідження database →Titration protocol to 12 mg (retatrutide (triple GLP-1 / GIP / glucagon agonist))
Starting dose (Phase 3 TRIUMPH)
First increase
Second increase
Maximum studied dose
Injection once weekly (per study protocol), subcutaneous (abdomen, thigh or upper arm). Expected weight loss at 12 mg: ~24% over 48 weeks (Phase 2) (based on clinical studies).
Who is Retatrutide 12 mg for
- Retatrutide is an investigational drug (Phase 3), not yet approved by the FDA/EMA
- Triple GLP-1 / GIP / glucagon agonist — a unique mechanism of action
- For patients for whom single (Ozempic) or dual (Mounjaro) agonists did not deliver enough effect
- Strictly under medical supervision
Retatrutide 12 mg — compared to other doses
- Retatrutide 12 mg showed ~24% weight loss over 48 weeks (Phase 2, NEJM 2023)
- Compared to Mounjaro 15 mg (~22–26%) — a similar effect, but with a triple mechanism
- Key difference: retatrutide activates the glucagon receptor, increasing energy expenditure
- No final Phase 3 results yet — efficacy and safety are still being confirmed
FAQ about Retatrutide 12 mg (PEN PEPTIDE)
You can buy Retatrutide 12 mg PEN PEPTIDE at DOZA — a specialized online service. Orders are placed through the website cart or Telegram. Delivery across Ukraine with cold chain maintenance at 2–8°C.
Anastasia Shapoval
Metabolic Programs and Weight Control Specialist
Other Retatrutide dosages
DOZA client reviews for Retatrutide 12 mg (PEN PEPTIDE)
Retatrutide 12 mg (PEN PEPTIDE) — noticeable results in just 3 weeks. Cold chain delivery, everything neat. Thank you, DOZA!
Ordering Retatrutide 12 mg (PEN PEPTIDE) via DOZA — fast delivery across Ukraine. Consultant helped choose the right dose. Triple agonist works more effectively.
All client results →
Before/after photos · numbers · timelines · reviews
Other Retatrutide dosages
Buy Retatrutide 12 mg in Ukraine
Buy Retatrutide 12 mg (PEN PEPTIDE) — next-generation triple GLP-1/GIP/glucagon agonist from DOZA. Next-generation triple agonist · 12 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE. Dosage 12 mg — for optimal therapeutic effect. Order via DOZA online service, delivery 1–2 days.
Retatrutide 12 mg (PEN PEPTIDE) price — 14 500 ₴.Cold chain delivery in thermal box.
Free DOZA specialist consultation. Available 24/7.
Buy Retatrutide 12 mg (PEN PEPTIDE) in Ukraine — DOZA online service with delivery in 1–2 days. Specialist consultation included.
⚠️ Retatrutide is an investigational product currently undergoing Phase 3 clinical trials. Results may vary. Consult a specialist before starting the program. Retatrutide is currently undergoing large-scale Phase 3 clinical trials (the TRIUMPH program). Final regulatory approval is expected after the completion of trials.